

The value of vaccination

Boosts NHS efficiency and helps cut waiting lists¹

Supports productivity and economic growth

One of the most effective public health interventions in modern times⁵

Vaccination programmes offer unparalleled value for money.²



The NHS saves an estimated **£400m annually** from some vaccination programmes.²

Saved bed days from vaccinating older adults against flu, pneumococcal disease and RSV would enable **14,500 patients to be admitted to hospital for other reasons.**¹



RSV causes winter pressures and cancelled operations for children.

Vaccination is expected to lead to:

5,000 fewer hospitalisations
15,000 fewer A&E attendances for infants.³




First five years of the shingles programme:

49,000 fewer GP visits



£10.5m estimated savings for the NHS.⁴

Globally, immunisation has saved an estimated **6 lives every minute** for the past 50 years.⁶



59% fall in mortality from infectious diseases in Europe from 1980–2019 directly resulted from vaccination.⁷




The UK is close to defeating meningococcal group C (MenC) disease:

99% fall in cases since NHS vaccination began in 1999.⁸



Eliminate cervical cancer by 2040

HPV vaccination reduces cervical cancer rates by **87%** in women offered the jab between ages 12–13.⁹



50% reduction in deaths from antimicrobial resistance among children under five from 1990–2021, helped by widespread vaccination.¹⁰

Adult vaccination programmes generate up to **19x return on investment** by preventing death, serious disease and productivity losses.¹¹



Working people with flu-like illness take **2 to 5 days of sick leave** leading to substantial impact on economic growth. **Vaccination can prevent flu.**¹²

COVID-19 2021–22 vaccination programme:
223,000 sick days averted **£26.3m economic benefit.**¹³



7.5 days off work taken by carers of children with rotavirus-positive gastroenteritis. Cases can be substantially reduced by vaccination.¹⁴



Vaccinated children **attend school more regularly, and get better grades**, compared with unvaccinated children.¹⁵



1. Neri M, Brassel S, Schirmacher H et al., 'Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?', Vaccines, Vol 11, 5, 945, 2023. 2. UKHSA, 'UKHSA Advisory Board: Immunisation Schedule', May 2024, accessed Nov 2024, available at <https://www.gov.uk/government/publications/ukhsa-advisory-board-agenda>. 3. NHS England, 'Press Release', 21 Nov 2024, accessed Nov 2024, available at <https://www.england.nhs.uk/2024/11/more-than-one-million-people-get-rsv-jab-in-first-ever-nhs-rollout/>. 4. Andrews N, Stowe J, Kuyumdzhiava G et al., 'Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study', BMJ Open, 10, e037458, 2020. 5. NHS England, 'Shaping the future delivery of NHS vaccination services', 13 Dec 2023, available at <https://www.england.nhs.uk/long-read/nhs-vaccination-strategy/>. 6. World Health Organization, 'News Release 24 April 2024', available at <https://www.who.int/news/item/24-04-2024-global-immunization-efforts-have-saved-at-least-154-million-lives-over-the-past-50-years>. 7. The European House Ambrossetti, 'The value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems', Sep 2024, accessed Nov 2024, available at https://www.vaccineurope.eu/wp-content/uploads/2024/09/240906_PAPER_Value-of-prevention_DE5.pdf. 8. UKHSA, 'UK on brink of defeating meningococcal C', accessed Dec 2024, available at <https://www.gov.uk/government/news/uk-on-brink-of-defeating-meningococcal-c>. 9. Kings College London, 'HPV vaccine reduces cervical cancer by 87%', accessed Dec 2024, available at <https://www.kcl.ac.uk/news/hpv-vaccine-reduces-cervical-cancer-by-87>. 10. GBD 2021 Antimicrobial Resistance Collaborators, 'Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050', The Lancet, Vol 404, 10459, 1199–1226, 28 Sep 2024. 11. El Banhawi H, Chowdhury S, Neri M et al., 'Socio-Economic Value of Adult Immunisation Programmes', accessed Nov 2024, available at <https://www.who.org/publications/the-socio-economic-value-of-adult-immunisation-programmes/>. 12. Quilici S, Smith R, and Signorelli C, 'Role of vaccination in economic growth', Journal of Market Access & Health Policy, vol 3, 1, 2015. 13. Future Health, 'Vaccination: Putting the vaccination triple-win at the heart of the new Government's policy agenda', accessed Nov 2024, available at <https://www.futurehealth-research.com/site/wp-content/uploads/2024/09/Vaccine-Report-FINAL-DESIGN.pdf>. 14. Van der Wielen M, Giaquinto C, Gotheffers L et al, REVEAL Study Group, 'Impact of community-acquired rotavirus gastroenteritis on family life: data from the REVEAL study', BMC Family Practice, vol 11, 22, 2010. 15. Rodrigues CMC and Plotkin SA, 'Impact of Vaccines: Health, Economic and Social Perspectives', Frontiers in microbiology, vol 11, 1526, 14 Jul 2020.